This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A compound of formula (1):

$$L^{2}Ar^{2}Alk - N \qquad L^{1}(Alk^{1})_{n}R_{2}$$

$$(R^{16})_{g} \qquad O \qquad O \qquad (1)$$

wherein

Het is a bicyclic fused ring heteroaromatic group;

g is zero or the integer 1, 2, 3 or 4;

Each R^{16} , which may be the same or different, is an atom or group $-L^3(Alk^2)_tL^4(R^4)_u$,

L³ and L⁴, which may be the same or different, are each a covalent bond or a linker atom or group -O-, -S-, -C(O)-, -C(O)O-, -OC(O)-, -C(S)-, -S(O)-, -S(O)₂-, -N(R⁸)-, -N(R⁸)O-, -N(R⁸)N-, -CON(R⁸)-, -OC(O)N(R⁸)-, -CSN(R⁸)-, -N(R⁸)CO-, -N(R⁸)CO-, -N(R⁸)CO)₂-, -N(R⁸)CON(R⁸)-, -N(R⁸)CSN(R⁸)-, or -N(R⁸)SO₂N(R⁸)-,

R⁸ is a hydrogen atom or an optionally substituted C₁₋₆alkyl group,

t is zero or the integer 1,

u is an integer 1, 2 or 3,

Alk² is an aliphatic or heteroaliphatic chain, and

 R^4 is a hydrogen or halogen atom or a group selected from an optionally substituted $C_{1\text{-}6}$ alkyl or $C_{3\text{-}8}$ cycloalkyl group, -OR⁵ (where R^5 is a hydrogen atom, an optionally

DOCKET NO.: CELL-0113 **Application No.:** 09/899,488

Office Action Dated: August 7, 2003

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116

substituted C_{1-6} alkyl or C_{3-8} cycloalkyl group), $-SR^5$, $-NR^5R^6$ (where R^6 is as just defined for R^5 and may be the same or different), $-NO_2$, -CN, $-CO_2R^5$, $-SO_3H$, $-SOR^5$, SO_2R^5 , $-SO_3R^5$, $-OCO_2R^5$, $-CONR^5R^6$, $-OCONR^5R^6$, $-CSNR^5R^6$, $-COR^5$, $-OCOR^5$, $-N(R^5)COR^6$, $-N(R^5)CSR^6$, $-SO_2N(R^5)(R^6)$, $-N(R^5)SO_2R^6$, $N(R^5)CON(R^6)(R^7)$ (where R^7 is a hydrogen atom, an optionally substituted C_{1-6} alkyl or C_{3-8} cycloalkyl group), $-N(R^5)CSN(R^6)(R^7)$ or $-N(R^5)SO_2N(R^6)(R^7)$,

provided that when t is zero and each of L^3 and L^4 is a covalent bond then u is the integer 1 and R^4 is other than a hydrogen atom;

 L^2 is a covalent bond or an atom or group -O-, -S-, -C(O)-, -C(S)-, -S(O)-, -S(O)₂, -N(R⁸)- or -C(R⁸)(R^{8a})- (where R^{8a} is an atom or group as defined for R⁸ and may be the same or different);

Ar² is an optionally substituted aromatic or heteroaromatic group;

Alk is a chain

in which R is a carboxylic acid (-CO₂H), a carboxylic acid ester, a carboxylic acid amide, or a carboxylic acid biostere;

R¹ is a hydrogen atom or a C₁₋₆alkyl group;

L¹ is a covalent bond or a linker atom or group -O-, -S-, -C(O)-, -C(O)O-, -OC(O)-, -C(S)-, -S(O)-, -S(O)₂-, -N(R⁸)-, -N(R⁸)O-, -N(R⁸)N-, -CON(R⁸)-, -OC(O)N(R⁸)-, -CSN(R⁸)-, -N(R⁸)CO-, -N(R⁸)C(O)O-, -N(R⁸)CS-, -S(O)₂N(R⁸)-, -N(R⁸)S(O)₂-, -N(R⁸)CON(R⁸)-, -N(R⁸)CSN(R⁸)-, or -N(R⁸)SO₂N(R⁸)-;

Alk¹ is an optionally substituted aliphatic chain;

DOCKET NO.: CELL-0113 **Application No.:** 09/899,488

Office Action Dated: August 7, 2003

PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

n is zero or the integer 1;

R² is a hydrogen atom or an optionally substituted heteroaliphatic, C₃₋₁₀-eyeloalkyl, C₃₋₁₀-eyeloalkyl, C₃₋₁₀-heterocycloalkyl, C₃₋₁₀-heterocycloalkyl, C₃₋₁₀-heterocycloalkyl, C₃₋₁₀-heterocycloalkyl, C₃₋₁₀-heteroalkyl, C₃₋₁₀-heteroalkyl, C₃₋₁₀-heteroalkyl, C₃₋₁₀-heteroalkenyl, C₃₋₁₀-heterocycloaliphatic, C₃₋₁₀-heterocycloaliphatic, C₃₋₁₀-heterocycloaliphatic, aromatic or heteroaromatic group, wherein said heteroaliphatic, heterocycloalkyl, heterocycloalkenyl, bicycloheteroalkyl, tricycloheteroalkyl, bicycloheteroalkyl, bicycloheteroalkyl, tricycloheteroalkyl, bicycloheteroalkyl, tricycloheteroalkyl, heterocycloaliphatic groups contain one, two, three, or four heteroatoms or heteroatom-containing groups as defined for L³ and L⁴, which may be the same or different;

provided that Het is not a 2,6-naphthyridin-1-yl, isoquinolin-1-yl, 2,7-naphthyridin-1-yl or quinazolin-4-yl group;

and the salts and N-oxides thereof.

2. (original) A compound according to Claim 1 in which Alk is a chain

3. (original) A compound according to Claim 1 in which R is a carboxylic acid (-CO₂H) group.

DOCKET NO.: CELL-0113

Application No.: 09/899,488

Office Action Dated: August 7, 2003

PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

- 4. (original) A compound according to Claim 1 in which R is an esterified carboxyl group of formula -CO₂Alk⁷.
- 5. (original) A compound according to Claim 1 in which R¹ is a hydrogen atom.
- 6. (original) A compound according to Claim 1 in which Ar² is an optionally substituted phenylene group.
- 7. (original) A compound according to Claim 1 in which L^1 is a -N(R^8)- group where R^8 is a hydrogen atom or an optionally substituted C_{1-6} alkyl group.
- 8. (original) A compound according to Claim 7 in which R⁸ is a methyl, ethyl, or n-propyl group.
- 9. (original) A compound according to Claim 1 in which L¹ is a covalent bond.
- 10. (original) A compound according to Claim 1 in which n is the integer 1, Alk^1 is an optionally substituted straight or branched C_{1-6} alkylene chain and R^2 is a hydrogen atom.
- 11. (original) A compound according to Claim 10 in which Alk¹ is a -CH₂-, -CH₂CH₂-, -CH₂CH₂-, -CH(CH₃)CH₂- or -C(CH₃)₂CH₂- chain.

- 12. (currently amended) A compound according to Claim 1 in which L^1 is a covalent bond, n is zero and R^2 is an optionally substituted C_{5-7} heterocycloalkenyl C_{5-7} heterocycloaliphatic group.
- 13. (original) A compound according to Claim 12 in which R² is an optionally substituted piperidinyl, homopiperidinyl, heptamethyleneiminyl, pyrrolidinyl, piperazinyl, homopiperazinyl, morpholinyl or thiomorpholinyl group.
- 14. (original) A compound according to Claim 1 in which L^2 is an -O- atom or -N(R^8)-group in which R^8 is a hydrogen atom or an optionally substituted C_{1-6} alkyl group.
- 15. (previously presented) A compound according to Claim 1 of formula (2a):

wherein:

R¹⁷ is an atom or group R¹⁶ as previously defined;

h is zero or the integer 1, 2 or 3;

 R^{18} is a hydrogen atom or an atom or group R^{16} as previously defined; and the salts and N-oxides thereof.

16. (previously presented) A compound according to Claim 1 of formula (2b):

DOCKET NO.: CELL-0113 **Application No.:** 09/899,488

Office Action Dated: August 7, 2003

PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

wherein:

X, Y and Z are each independently selected from a nitrogen, oxygen or sulphur atom or CH group;

the broken line (---) represents saturation or unsaturation; and the salts and N-oxides thereof.

- 17. (original) A compound according to Claim 16 in which X is an O or S atom, Y and Z are each a group CH, a single bond joins X and Y and a double bond joins Y and Z.
- 18. (currently amended) A compound according to Claim 16 in which Z is an O or S atom, X and Y is are each a CH group, a single bond joins Y and Z and a double bond joins X and Y.
- 19. (previously presented) A compound which is:

S-2-{[2-Dipropylamino}-3,4-dioxo-1-cyclobutenyl]amino}-3-{4-[(1-methylbenzimidazol-2-yl)amino]phenyl}propanoic acid;

S-2-{[2-Dipropylamino)-3,4-dioxo-1-cyclobutenyl]amino}-3-{4-[(1-methylbenzimidazol-2-yl)amino]phenyl}propanoic acid; Page 7 of 14

DOCKET NO.: CELL-0113

Application No.: 09/899,488

Office Action Dated: August 7, 2003

PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

S-2-{[2-(2-Methylpiperidin-1-yl)-3,4-dioxo-1-cyclobutenyl]amino}-3-{4-[(1-methylbenzimidazol-2-yl)amino]phenyl}propanoic acid;

(S)-3-[4-(Thiophen[2,3-d]pyrimidin-4-ylamino)phenyl]2-(2-(diethylamino-3, 4-dioxocyclobut-1-enylamino)propanoic acid;

and the salts, N-oxides and carboxylic acid esters thereof.

- 20. (original) A pharmaceutical composition comprising a compound according to Claim

 1 together with one or more pharmaceutically acceptable carriers, excipients or diluents.
- 21. (previously presented) A method for the treatment of inflammatory arthritis, allograft rejection, diabetes, inflammatory dermatoses, asthma or inflammatory bowel disease comprising administering to a mammal suffering from such a disease or disorder a therapeutically effective amount of a compound according to Claim 1.
- 22. (canceled)
- 23. (previously presented) A method according to Claim 21 wherein said inflammatory arthritis is selected from the group consisting of rheumatoid arthritis, vasculitis and polydermatomyositis.
- 24. (previously presented) A method according to Claim 21 wherein said inflammatory dermatoses are selected from the group consisting of psoriasis and dermatitis.

DOCKET NO.: CELL-0113 **Application No.:** 09/899,488

Office Action Dated: August 7, 2003

PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

- 25. (canceled)
- 26. (canceled)
- 27. (previously presented) A compound according to claim 19 wherein the carboxylic acid esters are selected from the group consisting of methyl, ethyl, propyl, and i-propyl.